Adams Respiratory Therapeutics "outperform," target price reduced

03/19/07 - RBC Capital Markets

NEW YORK, March 19 (newratings.com) - Analysts at RBC Capital Markets reiterate their "outperform" rating on Adams Respiratory Therapeutics Inc (ARXT). The target price has been reduced from $55 to $35.